ARRIVENT BIOPHARMA, INC. Basic Shares Outstanding (Weighted Average)
ARRIVENT BIOPHARMA, INC. (AVBP) reported Basic Shares Outstanding (Weighted Average) of 47.61 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 47.61M shares, a 36.00% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 45.07M shares, a 32.95% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 42.94M shares, a 27.37% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 41.91M shares, a 24.81% increase year-over-year.
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 38.46M shares, a 22.22% increase from fiscal 2024.
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 31.47M shares, a 1369.88% increase from fiscal 2023.
- ARRIVENT BIOPHARMA, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 2.14M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 47.61M shares 10-Q · filed 2026-08-12 | 46.35M shares 10-Q · filed 2026-08-12 | 45.21M shares derived: average of 3 quarters · filed 2026-08-12 | 44.38M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 45.07M shares 10-Q · filed 2026-05-11 | 44.01M shares derived: average of 2 quarters · filed 2026-05-11 | 43.31M shares derived: average of 3 quarters · filed 2026-05-11 | 41.23M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 42.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 42.43M shares derived: average of 2 quarters · filed 2026-03-05 | 39.95M shares derived: average of 3 quarters · filed 2026-08-12 | 38.46M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 41.91M shares 10-Q · filed 2025-11-10 | 38.46M shares derived: average of 2 quarters · filed 2026-08-12 | 36.97M shares 10-Q · filed 2025-11-10 | 36.13M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 35.01M shares 10-Q · filed 2026-08-12 | 34.46M shares 10-Q · filed 2026-08-12 | 34.21M shares derived: average of 3 quarters · filed 2026-08-12 | 34.05M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 33.90M shares 10-Q · filed 2026-05-11 | 33.81M shares derived: average of 2 quarters · filed 2026-05-11 | 33.73M shares derived: average of 3 quarters · filed 2026-05-11 | 33.67M shares derived: average of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 33.72M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 33.65M shares derived: average of 2 quarters · filed 2026-03-05 | 33.60M shares derived: average of 3 quarters · filed 2026-03-05 | 31.47M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 33.58M shares 10-Q · filed 2025-11-10 | 33.54M shares derived: average of 2 quarters · filed 2025-11-10 | 30.72M shares 10-Q · filed 2025-11-10 | 23.71M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | 33.50M shares 10-Q · filed 2025-08-11 | 29.27M shares 10-Q · filed 2025-08-11 | 20.42M shares derived: average of 3 quarters · filed 2025-08-11 | 15.97M shares derived: average of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | 25.05M shares 10-Q · filed 2025-05-12 | 13.88M shares derived: average of 2 quarters · filed 2025-05-12 | 10.12M shares derived: average of 3 quarters · filed 2025-05-12 | 8.09M shares derived: average of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | 2.72M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 2.66M shares derived: average of 2 quarters · filed 2025-03-03 | 2.44M shares derived: average of 3 quarters · filed 2025-03-03 | 2.14M shares 10-K · filed 2025-03-03 |
| 2023-09-30 | 2.61M shares 10-Q · filed 2024-11-14 | 2.30M shares derived: average of 2 quarters · filed 2024-11-14 | 1.95M shares 10-Q · filed 2024-11-14 | |
| 2023-06-30 | 2.00M shares 10-Q · filed 2024-08-14 | 1.64M shares 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | 1.29M shares 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |